Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trail of Sorafenib Combined With Transarterial Chemoembolization in HBV-infected Patients With Intermediate Hepatocellular Carcinoma

NCT01556815 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT01556815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01556815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trail of Sorafenib Combined With Transarterial Chemoembolization in HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2012
Completion date
May 31, 2015
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, carcinoma, carcinoma, hepatocellular, digestive system neoplasms, doxorubicin/trastuzumab [va drug interaction], hbv, liver diseases, liver neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, glandular and epithelial, phenytoin/sorafenib [va drug interaction]